Trials / Terminated
TerminatedNCT04761679
Nasal Bridge Pressure Injury Prevention
Nasal Bridge Pressure Injury Prevention Using Protective Dressing and Halyard Fluidshield N95 Mask
- Status
- Terminated
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Columbia University · Academic / Other
- Sex
- All
- Age
- 18 Years – 64 Years
- Healthy volunteers
- Not accepted
Summary
The primary goal of this study is to explore whether applying the Mepilex foam on the nasal bridge directly between the skin and the N95 mask will prevent nasal bridge pressure injury among nursing staff, secondary to long-term ( \>8+ hours) wear time. The secondary goal is to evaluate if using the Mepilex maintains the seal of the mask.
Detailed description
Nurses use the N95 Mask as part of the personal protective equipment (PPE) when caring for patients with COVID-19. The N95 mask covers their nose and mouth with a tight seal. Nurses wear the mask for more than 8 hours per day, as a result they are at increased risk for skin injury on the nasal bridge. Mepliex is foam dressing which has been used to prevent pressure injuries to the skin. This study will evaluate if using Mepilex or band-aid on the nasal bridge of the nurses who wear the N95 for more than 8 hours decreases the potential for skin injury. In addition, the investigators will test if the Mepilex or band-aid also maintains the seal of the mask. Maintaining the seal is important to ensure that the nurse is not exposed to the virus. The investigators will be working with nurses who do not directly take care of COVID-19 patients to ensure the safety of all participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | Applying the Mepilex foam | Mepilex foam will be directly applied on the nasal bridge directly between the skin and the N95 mask. |
Timeline
- Start date
- 2021-03-23
- Primary completion
- 2022-01-04
- Completion
- 2022-01-04
- First posted
- 2021-02-21
- Last updated
- 2022-05-19
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT04761679. Inclusion in this directory is not an endorsement.